Literature DB >> 29454073

The accumulation of assembly intermediates of the mitochondrial complex I matrix arm is reduced by limiting glucose uptake in a neuronal-like model of MELAS syndrome.

Guillaume Geffroy1, Rayane Benyahia1, Samuel Frey1, Valerie Desquiret-Dumas2, Naig Gueguen2, Celine Bris2, Sophie Belal1, Aurore Inisan1, Aurelie Renaud1, Arnaud Chevrollier1, Daniel Henrion1, Dominique Bonneau2, Franck Letournel3, Guy Lenaers1, Pascal Reynier2, Vincent Procaccio4.   

Abstract

Ketogenic diet (KD) which combined carbohydrate restriction and the addition of ketone bodies has emerged as an alternative metabolic intervention used as an anticonvulsant therapy or to treat different types of neurological or mitochondrial disorders including MELAS syndrome. MELAS syndrome is a severe mitochondrial disease mainly due to the m.3243A > G mitochondrial DNA mutation. The broad success of KD is due to multiple beneficial mechanisms with distinct effects of very low carbohydrates and ketones. To evaluate the metabolic part of carbohydrate restriction, transmitochondrial neuronal-like cybrid cells carrying the m.3243A > G mutation, shown to be associated with a severe complex I deficiency was exposed during 3 weeks to glucose restriction. Mitochondrial enzyme defects were combined with an accumulation of complex I (CI) matrix intermediates in the untreated mutant cells, leading to a drastic reduction in CI driven respiration. The severe reduction of CI was also paralleled in post-mortem brain tissue of a MELAS patient carrying high mutant load. Importantly, lowering significantly glucose concentration in cell culture improved CI assembly with a significant reduction of matrix assembly intermediates and respiration capacities were restored in a sequential manner. In addition, OXPHOS protein expression and mitochondrial DNA copy number were significantly increased in mutant cells exposed to glucose restriction. The accumulation of CI matrix intermediates appeared as a hallmark of MELAS pathophysiology highlighting a critical pathophysiological mechanism involving CI disassembly, which can be alleviated by lowering glucose fuelling and the induction of mitochondrial biogenesis, emphasizing the usefulness of metabolic interventions in MELAS syndrome.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AICAR; Complex I assembly; Glucose restriction; Ketogenic diet; MELAS syndrome; Mitochondrial diseases

Mesh:

Substances:

Year:  2018        PMID: 29454073     DOI: 10.1016/j.bbadis.2018.02.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  4 in total

1.  Ketogenic treatment reduces the percentage of a LHON heteroplasmic mutation and increases mtDNA amount of a LHON homoplasmic mutation.

Authors:  Sonia Emperador; Ester López-Gallardo; Carmen Hernández-Ainsa; Mouna Habbane; Julio Montoya; M Pilar Bayona-Bafaluy; Eduardo Ruiz-Pesini
Journal:  Orphanet J Rare Dis       Date:  2019-06-21       Impact factor: 4.123

2.  Glutamate-Induced Deregulation of Krebs Cycle in Mitochondrial Encephalopathy Lactic Acidosis Syndrome Stroke-Like Episodes (MELAS) Syndrome Is Alleviated by Ketone Body Exposure.

Authors:  Sophie Belal; David Goudenège; Cinzia Bocca; Florent Dumont; Juan Manuel Chao De La Barca; Valérie Desquiret-Dumas; Naïg Gueguen; Guillaume Geffroy; Rayane Benyahia; Selma Kane; Salim Khiati; Céline Bris; Tamas Aranyi; Daniel Stockholm; Aurore Inisan; Aurélie Renaud; Magalie Barth; Gilles Simard; Pascal Reynier; Franck Letournel; Guy Lenaers; Dominique Bonneau; Arnaud Chevrollier; Vincent Procaccio
Journal:  Biomedicines       Date:  2022-07-11

Review 3.  Towards a therapy for mitochondrial disease: an update.

Authors:  Caterina Garone; Carlo Viscomi
Journal:  Biochem Soc Trans       Date:  2018-10-08       Impact factor: 5.407

Review 4.  Epilepsy in Mitochondrial Diseases-Current State of Knowledge on Aetiology and Treatment.

Authors:  Dorota Wesół-Kucharska; Dariusz Rokicki; Aleksandra Jezela-Stanek
Journal:  Children (Basel)       Date:  2021-06-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.